Following the data: lessons learned from the development of afami-cel

With Adaptimmune’s afami-cel on the verge of making history as both the first approved engineered TCR-T cell therapy and the first cellular immunotherapy to be approved for a solid tumor indication, CSO Jo Brewer tells David McCall (Senior Editor, BioInsights) about the long and winding road to market for this ground-breaking product, and shares some insights gleaned along the way.

Please enter your email to access content Read now